TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: RAVUM    
Ravulizumab Complement Blockage Monitoring, Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

Monitoring of complement blockage by ravulizumab

 

Investigation of suspected alternative pathway complement deficiency, atypical hemolytic uremic syndrome, C3 glomerulonephritis, dense-deposit disease

Highlights

Ravulizumab is a new complement C5 inhibitor therapeutic monoclonal antibody with a longer half-life than eculizumab. Monitoring complete complement blockade by eculizumab has allowed personalized therapy in specific settings. Similar action is expected with ravulizumab. Ravulizumab has 4 different amino acids from eculizumab, which allow greater affinity for the FcRn immunoglobulin receptor and change the affinity of the molecule for C5.

Method Name A short description of the method used to perform the test

Enzyme-Linked Immunosorbent Assay (ELISA)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

No

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

Ravulizumab Complement Blockage, S

Aliases Lists additional common names for a test, as an aid in searching

aHUS
Alternate Pathway Complement
Alternative Pathway
Functional Complement